Table 2 Summarizing key preclinical studies targeting major molecular pathways implicated in driving liver fibrosis progression
From: Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis
Target pathway/mediator | Model system | Intervention strategy | Outcomes on fibrosis markers |
|---|---|---|---|
TGF-β signaling | CCl4 mouse model | Anti-TGF-β neutralizing antibody | ↓ Hepatic collagen I/III, ↓ α-SMA, ↓ Fibrosis histology score |
TGF-β signaling | Bile duct ligation rat model | TGF-β receptor kinase inhibitor (SB525334) | ↓ Collagen, ↓ TIMP-1, ↑ MMPs |
Inflammation (TNF-α) | CCl4 mouse model | Anti-TNF monoclonal antibody (Infliximab) | ↓ Serum TGF-β1, ↓ Fibrosis area |
Oxidative stress | CCl4 mouse model | Mitochondrial-targeted antioxidant (MitoQ) | ↓ Hydroxyproline, ↓ α-SMA immunostaining |
Epithelial-mesenchymal transition | In vitro model | Transcription factor Zeb1 siRNA | ↓ Collagen 1, ↓ Fibronectin |